Evidence map›Paper›PMID 26903515›Full record

ArticleThe Journal of biological chemistry2016

Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS.

Luuk C T Dohmen, Adriana Navas, Deninson Alejandro Vargas, David J Gregory, Anke Kip, Thomas P C Dorlo, Maria Adelaida Gomez

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Luuk C T DohmenFrom the Centro Internacional de Entrenamiento e Investigaciones Médicas, Cra. 125 # 19-225 Cali, Colombia, the Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3508 TB Utrecht, The Netherlands.
Adriana NavasFrom the Centro Internacional de Entrenamiento e Investigaciones Médicas, Cra. 125 # 19-225 Cali, Colombia.
Deninson Alejandro VargasFrom the Centro Internacional de Entrenamiento e Investigaciones Médicas, Cra. 125 # 19-225 Cali, Colombia.
David J Gregorythe Molecular and Integrative Physiological Sciences, Harvard T. H. Chan School of Public Health, Boston, Massachusetts 02115.
Anke Kipthe Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3508 TB Utrecht, The Netherlands, the Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek Hospital/Slotervaart Hospital, 1066 CX Amsterdam, The Netherlands, and.
Thomas P C Dorlothe Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3508 TB Utrecht, The Netherlands, the Department of Pharmaceutical Biosciences, Uppsala University, 751 24 Uppsala, Sweden.
Maria Adelaida GomezFrom the Centro Internacional de Entrenamiento e Investigaciones Médicas, Cra. 125 # 19-225 Cali, Colombia, mgomez@cideim.org.co.
Centro Internacional de Entrenamiento e Investigaciones Medicas · COUtrecht University · NLThe Netherlands Cancer Institute · NL

Funding

Vector/Host-Parasite Interface of Leishmaniasis in ColombiaD43TW006589 · FIC · YALE UNIVERSITY · PI GORE SARAVIA, NANCY, TSCHUDI, CHRISTIAN · 2003 to 2024
$4.3M
Macrophage drug transport and metabolism in the outcome of antileishmania therapyR01AI104823 · NIAID · CENTRO INTERNACIONAL (CIDEIM) · PI GOMEZ, MARIA ADELAIDA · 2013 to 2017
$674k
FIC NIH HHS D43 TW006589NIAID NIH HHS R01 AI104823
6 · The paper itself

Abstract

Within its mammalian host, Leishmania resides and replicates as an intracellular parasite. The direct activity of antileishmanials must therefore depend on intracellular drug transport, metabolism, and accumulation within the host cell. In this study, we explored the role of human macrophage transporters in the intracellular accumulation and antileishmanial activity of miltefosine (MLF), the only oral drug available for the treatment of visceral and cutaneous leishmaniasis (CL). Membrane transporter gene expression in primary human macrophages infected in vitro with Leishmania Viannia panamensis and exposed to MLF showed modulation of ABC and solute liquid carrier transporters gene transcripts. Among these, ABCA3, a lipid transporter, was significantly induced after exposure to MLF, and this induction was confirmed in primary macrophages from CL patients. Functional validation of MLF as a substrate for ABCA3 was performed by shRNA gene knockdown (KD) in THP-1 monocytes. Intracellular accumulation of radiolabeled MLF was significantly higher in ABCA3(KD) macrophages. ABCA3(KD) resulted in increased cytotoxicity induced by MLF exposure. ABCA3 gene expression inversely correlated with intracellular MLF content in primary macrophages from CL patients. ABCA3(KD) reduced parasite survival during macrophage infection with an L. V. panamensis strain exhibiting low in vitro susceptibility to MLF. Confocal microscopy showed ABCA3 to be located in the cell membrane of resting macrophages and in intracellular compartments in L. V. panamensis-infected cells. These results provide evidence of ABCA3 as an MLF efflux transporter in human macrophages and support its role in the direct antileishmanial effect of this alkylphosphocholine drug.

Indexed as

ATP-Binding Cassette TransportersBiological Transport, ActiveCell Line, TumorGene Knockdown TechniquesHumansLeishmaniaLeishmaniasisMacrophagesPhosphorylcholineABCA3 protein, humanATP-Binding Cassette TransportersmiltefosinePhosphorylcholineABCA3ABC transporterdrug transporthost-pathogen interactionLeishmaniamacrophagemiltefosinepharmacodynamics

Identifiers

PMID26903515
PMCPMC4850301
OpenAlexW2285664685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.